Federal Circuit Denies En Banc Rehearing of Biosimilar Opinion in Amgen v. Sandoz

Oct 15, 2015

Reading Time : 1 min

The original panel opinion interpreted two notice provisions in the Biologics Price Control and Innovation Act (BPCIA), a component of the ACA. At issue was Sandoz's decision not to comply with the first provision of the law, which states that the biosimilar applicant “shall” provide to the reference product sponsor a copy of its application and manufacturing information. Sandoz contended, and the court ultimately agreed, that despite using the word “shall,” Congress did not intend to make these disclosures mandatory, because the law also provided remedies for sponsors faced with non-disclosure from an applicant.

The panel also interpreted another provision of the law, requiring that the biosimilar applicant provide 180 day notice to the product sponsor that it intended to enter the marketplace. The panel held that biosimilar makers can only provide the BPCIA’s 180-day notice of commercial marketing after their product is licensed, and that this notice is mandatory when biosimilar makers do not participate in the so-called patent dance.

It is possible that Amgen and Sandoz will seek review by the U.S. Supreme Court, but it is not immediately clear whether either company will do so.

Amgen Inc. et al. v. Sandoz Inc., Case No. 15-1499 (Fed. Cir. Oct. 16, 2015).

Share This Insight

Categories

Previous Entries

IP Newsflash

February 24, 2026

The Southern District of Florida recently dismissed a complaint without prejudice because the allegations used a form of “shotgun pleading.” The court explained that a shotgun pleading includes those where every count incorporates every preceding paragraph into each cause of action, and that dismissal of such pleadings was required under Eleventh Circuit precedent.

...

Read More

IP Newsflash

February 20, 2026

The Federal Circuit recently addressed whether the PTO must conduct notice‑and‑comment rulemaking before issuing instructions that guide how the Board should exercise discretion at the institution stage of IPRs. The court held that no such rulemaking is required. Instructions to the Board regarding its use of the Director’s delegated discretionary authority not to institute review are merely general statements of policy exempt from notice-and-comment rulemaking.  

...

Read More

IP Newsflash

February 18, 2026

The District Court for the District of Delaware recently invalidated claims directed to a panoramic objective lens for lack of enablement, holding the claims impermissibly recited a single element in means‑plus‑function form. Under § 112, ¶ 6, “[a]n element in a claim for a combination may be expressed as a means or step for performing a specified function….” By its plain terms, the statute permits means‑plus‑function claiming only in the context of a “combination.” In other words, a claim may not consist solely of a single means‑plus‑function element. Claims drafted as a single means are invalid for lack of enablement as a matter of law.

...

Read More

IP Newsflash

February 13, 2026

In an ANDA litigation, the District of Delaware recently denied the defendants’ motion to compel the production of correspondence between the plaintiffs’ testifying expert and a third-party analyst who had performed experiments and provided data used by the testifying expert. The court found that the scope of material sought by the motion was overbroad and disproportionate to the needs of the case.

...

Read More

© 2026 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.